Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascelia Pharma AB ( (SE:ACE) ) has issued an announcement.
Ascelia Pharma AB has increased its registered number of shares and votes following a directed new issue of ordinary shares completed in April 2026. As of 30 April 2026, the company has a total of 134,569,246 shares outstanding, comprising 133,535,460 ordinary shares with one vote each and 1,033,786 series C shares with one-tenth of a vote each, resulting in a total of 133,638,838.6 votes, which may impact ownership structure and future capital market activities.
The change in share capital underscores Ascelia Pharma’s ongoing efforts to finance the development of its orphan oncology pipeline, including its key candidates Orviglance and Oncoral. By expanding its equity base through a targeted share issue, the company strengthens its financial flexibility to pursue clinical development and commercialization plans, a move that is closely watched by investors in the biotech and oncology segments.
More about Ascelia Pharma AB
Ascelia Pharma AB is a biotech company specializing in orphan oncology treatments, developing and commercializing novel drugs for unmet medical needs with defined development and market pathways. The company’s pipeline includes two drug candidates, Orviglance and Oncoral, and it is headquartered in Malmö, Sweden, with its shares listed on Nasdaq Stockholm under the ticker ACE.
Average Trading Volume: 720,732
Technical Sentiment Signal: Sell
Current Market Cap: SEK373M
For detailed information about ACE stock, go to TipRanks’ Stock Analysis page.